Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...
CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...
Hepatocellular carcinoma (HCC) is a highly prevalent and lethal cancer ... Evaluating the added value of liquid biopsy genetic and epigenetic biomarkers for HCC screening is a key goal in ...
The colors correspond to gene markers identified ... cancer with unique genetic traits, often misdiagnosed until advanced. New research and a clinical trial offer hope for effective treatments.
Recent studies have shown that ASF1B may be used as a new proliferation marker for cancer prognosis. However, the prognostic value and effect of ASF1B on tumor cells and the immune microenvironment in ...
This valuable study investigated the role of PLECTIN, a cytoskeletal crosslinker protein, in hepatocellular ... HCC marker associated with a malignant phenotype and poor survival. To explore the role ...
Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...
Even though a large proportion of cancer patients carry genetic mutations that make them more susceptible to cancer, only a small percentage of them — and their family members — undergo ...
More information: David Requena et al, Liver cancer multiomics reveals diverse protein kinase A disruptions convergently produce fibrolamellar hepatocellular carcinoma, Nature Communications (2024 ...
While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...